MeSH D002583 - uterine cervical neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Topotecan | Topotecan Teva | 2009-09-21 | |||
| Novast Laboratories | Topotecan | Topotecan | 2016-11-30 | |||
| Mylan | Bevacizumab | Abevmy | 2021-04-21 | |||
| Bevacizumab | Lextemy | |||||
| Rising Pharmaceuticals | Topotecan | Topotecan | 2012-08-28 | |||
| Roche | Bevacizumab | Avastin | 2005-01-12 | $1,988.958 M | Q4/22-Q3/23 | |
| Sandoz | Topotecan | Hycamtin | 1996-05-28 | |||
| Topotecan | Topotecan | 2011-02-25 | ||||
| Pfizer | Topotecan | Topotecan Hospira | 2010-06-09 | |||
| Bevacizumab | Zirabev | 2019-06-27 | $424 M | Y2023 | ||
| Dr Reddys Laboratories | Topotecan | Topotecan | 2011-03-09 | |||
| Sun Pharmaceutical Industries | Topotecan | Topotecan | 2013-08-29 | |||
| Hospira | Topotecan | Topotecan | 2011-02-02 |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
81%68/84
Phase 2
21%36/172
Phase 3
18%12/65
Approved: 2Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use